Can Tumor Vascularity be Targeted for Cancer Therapy?
Yes, targeting tumor vascularity is a promising strategy in cancer therapy. Anti-angiogenic drugs, such as Bevacizumab (an anti-VEGF antibody), aim to inhibit the formation of new blood vessels, thereby starving the tumor of nutrients and oxygen. Other strategies include blocking angiogenic signaling pathways and using vascular disrupting agents that damage existing tumor blood vessels.
